Cardiovascular Disease in HIV Patients: A Comprehensive Overview

For decades, human immunodeficiency virus (HIV) was primarily understood as a threat to the immune system. However, with advancements in antiretroviral therapy (ART) extending the lifespan of individuals living with HIV, cardiovascular disease (CVD) has emerged as a significant and growing health concern within this population. This article provides a comprehensive review of the relationship between HIV and CVD, exploring the underlying mechanisms, clinical manifestations, diagnostic approaches and treatment strategies.

The Rising Prevalence of CVD in People Living with HIV

The prevalence of cardiac involvement in individuals with AIDS has been reported to range between 28% and 73% ¹. Historically, CVD was less common in people with HIV due to the shorter survival times before the advent of effective ART. However, as individuals with HIV now live longer, more manifestations of cardiovascular disease are becoming apparent ¹. People living with HIV still face an increased incidence of cardiovascular pathology ².

Understanding the Pathogenesis of HIV-Associated CVD

The development of CVD in people living with HIV is multifactorial, involving both traditional cardiovascular risk factors and HIV-specific mechanisms. Traditional risk factors, such as hypertension, dyslipidemia, diabetes, and smoking, are often more prevalent in this population. However, HIV itself contributes to CVD through several pathways:

• Chronic Inflammation: HIV infection leads to chronic immune activation and inflammation, even in individuals on ART, which promotes atherosclerosis.
• Endothelial Dysfunction: HIV can directly damage the endothelium, the inner lining of blood vessels, impairing their function and increasing the risk of thrombosis.
• Viral Proteins: HIV proteins, such as gp120, can have direct toxic effects on cardiomyocytes (heart muscle cells), leading to cardiomyopathy.
• Immune Reconstitution Inflammatory Syndrome (IRIS): IRIS, which occurs when the immune system recovers with ART, can sometimes trigger inflammation that affects the heart.

Advances in cardiac imaging and immunology have deepened our understanding of these complex processes ².

Clinical Manifestations of CVD in HIV

HIV-associated CVD can manifest in various forms, including:

• Coronary Artery Disease (CAD): The most common form, leading to angina, myocardial infarction (heart attack), and heart failure.
• Cardiomyopathy: Weakening of the heart muscle, resulting in heart failure.
• Heart Failure: The heart’s inability to pump enough blood to meet the body’s needs.
• Arrhythmias: Irregular heartbeats.
• Pericardial Disease: Inflammation of the sac surrounding the heart.
• Valvular Heart Disease: Problems with the heart valves.

The clinical presentation can be atypical, making diagnosis challenging. Individuals with HIV may experience symptoms differently or have a lower threshold for developing heart failure ³.

Diagnosis and Management

Diagnosing CVD in people living with HIV requires a comprehensive approach, including:

• Thorough Medical History and Physical Examination: Assessing cardiovascular risk factors and symptoms.
• Electrocardiogram (ECG): To detect arrhythmias and signs of ischemia.
• Echocardiography: To evaluate heart structure and function.
• Cardiac Magnetic Resonance Imaging (MRI): Provides detailed images of the heart.
• Biomarkers: Measuring levels of cardiac troponins and natriuretic peptides.

Management focuses on addressing both traditional cardiovascular risk factors and HIV-specific considerations:

• Antiretroviral Therapy (ART): Effective viral suppression is crucial to reduce inflammation and gradual disease progression.
• Lifestyle Modifications: Diet, exercise, and smoking cessation.
• Pharmacological Interventions: Medications to control blood pressure, cholesterol, and diabetes.
• Cardiac Rehabilitation: A supervised program to improve cardiovascular health.

The Link Between HIV and Cardiomyopathy

Recent research highlights a significant link between HIV and cardiomyopathy, focusing on the molecular mechanisms, clinical manifestations, diagnostic approaches, and treatment strategies ⁴. This review investigates the pathogenesis of HIV-associated cardiomyopathy.

Looking Ahead

As the population of people living with HIV continues to age, the burden of CVD is expected to rise. Further research is needed to fully elucidate the complex interplay between HIV and the cardiovascular system, leading to improved prevention, diagnosis, and treatment strategies. A proactive and integrated approach to cardiovascular care is essential for optimizing the health and well-being of individuals living with HIV.